Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 30 Mar 2016 |
| Zealand convenes its Annual General Meeting for 2016 | 18 Mar 2016 |
| Zealand announces full year results in line with guidance and release of its Annual Report for 2015 | 16 Mar 2016 |
| Notice of release date and related conference call for Zealand’s 2015 Full Year results and Annual Report | 8 Mar 2016 |
| Zealand announces results of a Phase II Proof-of-Concept trial with danegaptide for cardiac reperfusion injuries | 2 Mar 2016 |
| Zealand presents at four international biotech/healthcare investor conferences in March and April 2016 | 26 Feb 2016 |